Developing combination immunotherapies against cancer that make sense

André Veillette; Dominique Davidson

doi:10.1126/sciimmunol.aav1872

Developing combination immunotherapies against cancer that make sense

Sci Immunol. 2018 Nov 2;3(29):eaav1872. doi: 10.1126/sciimmunol.aav1872.

Authors

André Veillette^{1

2

3}, Dominique Davidson⁴

Affiliations

¹ Laboratory of Molecular Oncology, Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec H2W1R7, Canada. andre.veillette@ircm.qc.ca.
² Department of Medicine, University of Montréal, Montréal, Québec H3C3J7, Canada.
³ Department of Medicine, McGill University, Montréal, Québec H3G 1Y6, Canada.
⁴ Laboratory of Molecular Oncology, Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec H2W1R7, Canada.

PMID: 30389799
DOI: 10.1126/sciimmunol.aav1872

Abstract

Mechanistic preclinical studies provide a compelling case that combination immunotherapies that target the receptors PD-1 and GITR may demonstrate synergy in human cancer.

Publication types

Research Support, Non-U.S. Gov't
Review
Comment

MeSH terms

CD8-Positive T-Lymphocytes
Humans
Immunotherapy
Neoplasms*
Phenotype
Programmed Cell Death 1 Receptor*
T-Lymphocytes

Substances

Programmed Cell Death 1 Receptor

Grants and funding

FDN-143338/CIHR/Canada